Key stats
About Roundhill GLP-1 & Weight Loss ETF
Home page
Inception date
May 21, 2024
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Roundhill Financial, Inc.
Distributor
Foreside Fund Services LLC
ISIN
US77926X8829
OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each companys public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.54%
Health Technology97.29%
Commercial Services2.25%
Bonds, Cash & Other0.46%
Mutual fund0.30%
Cash0.16%
Stock breakdown by region
North America46.96%
Europe35.96%
Asia17.09%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
OZEM invests in stocks. The fund's major sectors are Health Technology, with 97.29% stocks, and Commercial Services, with 2.25% of the basket. The assets are mostly located in the North America region.
OZEM top holdings are Novo Nordisk A/S Sponsored ADR Class B and Eli Lilly and Company, occupying 18.88% and 15.25% of the portfolio correspondingly.
Yes, OZEM pays dividends to its holders with the dividend yield of 0.20%. The last dividend (Dec 31, 2024) amounted to 0.05 USD. The dividends are paid annually.
OZEM shares are issued by Roundhill Financial, Inc. under the brand Roundhill. The ETF was launched on May 21, 2024, and its management style is Active.
OZEM expense ratio is 0.59% meaning you'd have to pay 0.59% of your investment to help manage the fund.
OZEM follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
OZEM invests in stocks.